Technology Review: In-Process Analytics for Advanced Therapies

28 September 2020

Edition Three of Phacilitate’s technology review series examines in-process analytics tools that will innovate and improve commercial-scale cell and gene therapy manufacturing. In partnership with Anemocyte.

We’re undoubtedly experiencing a period of innovation across the advanced therapies industry and with innovation comes added pressure to produce and perform. A big priority for the industry today is to refine large-scale manufacturing and commercialisation of life-saving and life-preserving advanced therapies.

In order to get commercially viable and sustainable advanced therapy products to market, multiple technological advances are needed, particularly in the realm of manufacturing. Such advances will allow for assessment of product quality early in the drug development process; not just at the later stages, where chances of wasted time and lost revenue can have serious implications.

The good news is that advanced therapies manufacturing is experiencing a digital revolution, from which stems a multitude of technological innovations that will pave the way for continuous improvement. A major feature of this is the development and integration of effective in-process analytical methods and tools. 

This third instalment of Phacilitate’s Technology Review series assesses nine tool and software providers that are leading in the innovation of in-process analytical methods. No single solution is a panacea, therefore, we shed some light on the advantages and disadvantages of these innovative technologies.

Whilst this is not an exhaustive list, we will focus on nine technology companies, as follows:

  1. Cytosmart
  2. Cytiva
  3. MerckMillipore
  4. Rockwell
  5. Siemens
  6. Synthace
  7. Thermo Fisher (Finesse)
  8. Vironova
  9. Wyatt Technologies

View the report